Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in Sweden / NCT06106555
Recruiting Observational

Which Factors Are Relevant for Treatment Outcome in Dialectical Behaviour Therapy for Borderline Personality Disorder?

NCT06106555 · tracked via the Priya Life Science Sweden tracker
Sponsor
Region Skane
Phase
Observational
Started
2023-09-01
Last updated
2025-06-25

Condition(s) studied

Borderline Personality DisorderNon-suicidal Self-injuryDeliberate Self Harm

Investigational drug(s) / intervention(s)

Dialectibal Behaviour Therapy

Dialectibal Behaviour Therapy: Standard Dialectical Behaviour Therapy of up to 12 months as described Professor Linehan

Study summary

The objective of this project is to investigate factors that contribute to the success and lack of success in DBT among individuals with BPD and a history of self-harm in a clinical psychiatric setting.

1. Do certain personality factors and identity disturbance predict the treatment outcome of DBT in individuals with BPD?
2. Do changes in identity disturbance, self-hate, or emotion regulation mediate the treatment outcome of DBT in individuals with BPD?
3. Do specific personality profiles moderate the treatment outcomes of DBT for individuals with BPD?
4. When does the primary treatment effect occur, and does this effect persist after a 12-month follow-up period?

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Borderline personality disorder as defined by the DSM-V (assessed with SCID or uquivalent). * Self-harm over the past 12 months * Offered DBT at the Lund adult psychiatric clinic Exclusion Criteria: * Unable to read or communicate in Swedish

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Lund adult psychiatric hospital Lund Skåne County Recruiting

More Region Skane trials in Sweden

Febrile Infants Swedish Study Recruiting
Intractable Self-harm-What Support is Effective? Recruiting
Monitoring and Early Response Evaluation Using HPV DNA - A Study on Patients With HPV-positive Throat Cancer (MER-HPV) Recruiting
Semaglutide and Dapagliflozin in Diabetic Patients With Different Pathophysiology Active, not recruiting
Assessment of Tiredness During Awake Resection of Intracerebral Tumors Recruiting

Other trials for the same condition

Effects of Psychiatric Admissions on Self-harm and Suicide in People With Borderline Personality Disorder Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06106555 on ClinicalTrials.gov ↗ ← All trials in Sweden